LABS — Medipharm Labs Balance Sheet
0.000.00%
- CA$31.56m
- CA$21.74m
- CA$41.96m
- 68
- 70
- 22
- 54
Annual balance sheet for Medipharm Labs, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 19.9 | 34.1 | 24.1 | 18 | 11.7 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 34.1 | 16.9 | 13 | 5.87 | 7.51 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 81.5 | 65.5 | 47.3 | 36.6 | 33.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 34.1 | 25.9 | 18.1 | 25.3 | 19.2 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 118 | 92.4 | 65.5 | 63.9 | 53.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 24.2 | 8.88 | 9.46 | 10.9 | 10.5 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 39.8 | 9.21 | 9.49 | 10.9 | 10.5 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 78.4 | 83.1 | 56 | 53 | 43.2 |
| Total Liabilities & Shareholders' Equity | 118 | 92.4 | 65.5 | 63.9 | 53.7 |
| Total Common Shares Outstanding |